Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.
|Videos|April 1, 2022
Presbyopia awareness: A deep dive with Brieann Adair, OD
Author(s)Sheryl Stevenson, Brieanne K. Adair, OD
Presbyopia awareness: Causes, risk factors, symptoms, correction options and market trends.
Advertisement
In celebration of Presbyopia Awareness Month, Brieann K. Adair, OD, of NYU Langone Health, speaks with Optometry Times' Sheryl Stevenson about the importance of Presbyopia awareness, causes of the condition, risk factors, symptoms, correction options and market trends.
Advertisement
Related to this article
Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.
For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.
Walline, American Academy of Optometry president, shares this year's conference attendance numbers, clinical pearls, and what he hopes to see in 2027.
Thomas Wong, OD, FAAO, details a session he presented alongside Ronald Gentile, MD, FACS, FASRS, at AAOpt 2026.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
Jamie Kuzniar, OD, FAAO, FSLS, discusses a case-based AAOpt 2026 session on scleral lens complications, fitting around cross-linking, and advice for new graduates.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves subcutaneous Enspryng for TED
2
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
3
The screen time question: What to ask and when to look deeper
4
A rapid fire look at research presented at AAOpt26
5